|
[Olaparib in ovarian cancer] |
Larrea N, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Larrea N, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Olaparib in ovarian cancer] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 542. 2017 Authors' conclusions Low quality evidence of shows that the use of olaparib in ovarian cancer did not show changes in overall survival. In patients with high-grade serous ovarian cancer, the use of olaparib as maintenance therapy after platinum-sensitive relapse, might improve progression-free survival, especially in patients with BRCA mutations (approximately four versus seven months). In patients with recurrent platinum-sensitive or resistant epithelial ovarian cancer who received three or more lines of chemotherapy, the use of olaparib as therapy would be associated to a higher rate of response.
There is no consensus on the indications recommended by the clinical practice guidelines consulted and on the indications approved by the different regulatory agencies either, although its indication as maintenance monotherapy after second-line chemotherapy in patients with platinum-sensitive, high-grade serous ovarian cancer with BRCA 1 or BRCA 2 mutation shows wider consensus. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000307 Date abstract record published 13/06/2017 |
|
|
|